Company intelligence / Profile preview

OMICS Biotech

Ownership: Private
Development stage: Other

Overview

The company has developed candidate drugs that reportedly outperform existing drugs in the same class in terms of efficacy, metabolic stability, and toxicity data. These new drugs are preparing to enter clinical trials.[2]

Therapeutic areas: Oncology
Modalities: Nucleic acid drugs
Industry: Biotech

Drug pipeline

1 asset

QQ58

IND

Indications: Solid tumors with DNA damage repair defects

Partnerships

Plans to establish collaborations with top domestic and international universities and research institutes[2]

Beyond the preview

Go deeper on OMICS Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OMICS Biotech.

Explore the full profile